|
|
|
|
| LEADER |
03088nam a22005775i 4500 |
| 001 |
978-3-642-24846-7 |
| 003 |
DE-He213 |
| 005 |
20151204153119.0 |
| 007 |
cr nn 008mamaa |
| 008 |
120103s2012 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783642248467
|9 978-3-642-24846-7
|
| 024 |
7 |
|
|a 10.1007/978-3-642-24846-7
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a QH573-671
|
| 072 |
|
7 |
|a PSF
|2 bicssc
|
| 072 |
|
7 |
|a SCI049000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 571.6
|2 23
|
| 100 |
1 |
|
|a Hübel, Andreas.
|e author.
|
| 245 |
1 |
0 |
|a Biopatent Law: Patent Strategies and Patent Management
|h [electronic resource] /
|c by Andreas Hübel, Thilo Schmelcher, Ulrich Storz.
|
| 264 |
|
1 |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg,
|c 2012.
|
| 300 |
|
|
|a XII, 44 p. 1 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a SpringerBriefs in Biotech Patents,
|x 2192-9904
|
| 505 |
0 |
|
|a Andreas Huebel: General Issues of Biotech Patents -- Thilo Schmelcher: Active and Passive Patent Strategies -- Ulrich Storz: Patent Lifetime Management, SPCs and Data Exclusivity.
|
| 520 |
|
|
|a Patents protecting biotechnological invention become ever more important. Because biotechnology has many differences with respect to other technologies, lessons learned in other fields of technology cannot simply be transferred to adopt a suitable strategy for dealing with biotechnology inventions. In this volume, general aspects of biopatent law will be discussed. This involves questions of patentability, including ethical issues and issues of technicality, as well as questions of patent exhaustion in cases were reproducible subject matter, like cells or seeds, is protected. Moreover, active and passive patent strategies are addressed. Further, insight will be given into patent lifetime management and additional protective measures, like supplementary protection certificates and data exclusivity. Here, strategies are discussed how market exclusivity can be extended as long as possible, which is particularly important for biopharmaceutical drugs, which create high R&D costs.
|
| 650 |
|
0 |
|a Life sciences.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
0 |
|a Biotechnology.
|
| 650 |
|
0 |
|a Biochemistry.
|
| 650 |
|
0 |
|a Cell biology.
|
| 650 |
|
0 |
|a Microbiology.
|
| 650 |
|
0 |
|a Commercial law.
|
| 650 |
1 |
4 |
|a Life Sciences.
|
| 650 |
2 |
4 |
|a Cell Biology.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 650 |
2 |
4 |
|a Microbiology.
|
| 650 |
2 |
4 |
|a Biochemistry, general.
|
| 650 |
2 |
4 |
|a Biotechnology.
|
| 650 |
2 |
4 |
|a Commercial Law.
|
| 700 |
1 |
|
|a Schmelcher, Thilo.
|e author.
|
| 700 |
1 |
|
|a Storz, Ulrich.
|e author.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783642248450
|
| 830 |
|
0 |
|a SpringerBriefs in Biotech Patents,
|x 2192-9904
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-642-24846-7
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
